no information available
• Comprehensive and up-to-date coverage of the epidemiology, molecular pathogenesis, and cytogenetics of ALL <br/><br/>• Extensive discussion of clinical trial data in childhood and adult ALL <br/><br/>• Chapters devoted to in-depth coverage of key aspects of therapy including use of asparaginase, treatment of central nervous system ALL, and management of long-term sequelae <br/><br/>• Detailed coverage of emerging areas including minimal residual disease monitoring and pharmacogenomics <br/><br/>• Discussion of novel therapies including bispecific T-cell engaging antibody therapy and chimeric antigen receptor expressing T-cell therapy.
